WO2005097745A1 - Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives - Google Patents
Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives Download PDFInfo
- Publication number
- WO2005097745A1 WO2005097745A1 PCT/US2005/010501 US2005010501W WO2005097745A1 WO 2005097745 A1 WO2005097745 A1 WO 2005097745A1 US 2005010501 W US2005010501 W US 2005010501W WO 2005097745 A1 WO2005097745 A1 WO 2005097745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- chiral
- formula
- binap
- ligand
- Prior art date
Links
- 0 *c1cc(F)cc2c1[n](*)c1c2C*C[C@@]1CC(O)=O Chemical compound *c1cc(F)cc2c1[n](*)c1c2C*C[C@@]1CC(O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602005004393T DE602005004393T2 (en) | 2004-04-02 | 2005-03-29 | METHOD FOR ASYMMETRIC HYDROGENATION SUITABLE FOR THE PREPARATION OF CYCLOALKANINDOL DERIVATIVES |
CN2005800108462A CN1942440B (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
PL05732832T PL1737820T3 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
DK05732832T DK1737820T3 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for preparing cycloalkanoindole derivatives |
BRPI0509384-8A BRPI0509384A (en) | 2004-04-02 | 2005-03-29 | asymmetric hydrogenation process for the preparation of a compound or a salt thereof, and a compound or a salt thereof |
CA002561632A CA2561632A1 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
AU2005230897A AU2005230897B2 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
JP2007506467A JP5239071B2 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation methods useful for the preparation of cycloalkanoindole derivatives |
EP05732832A EP1737820B1 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
HR20080145T HRP20080145T3 (en) | 2004-04-02 | 2008-03-28 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55897204P | 2004-04-02 | 2004-04-02 | |
US60/558,972 | 2004-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097745A1 true WO2005097745A1 (en) | 2005-10-20 |
Family
ID=34964828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/010501 WO2005097745A1 (en) | 2004-04-02 | 2005-03-29 | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
Country Status (19)
Country | Link |
---|---|
US (1) | US7576118B2 (en) |
EP (1) | EP1737820B1 (en) |
JP (1) | JP5239071B2 (en) |
CN (1) | CN1942440B (en) |
AR (1) | AR048459A1 (en) |
AT (1) | ATE384046T1 (en) |
AU (1) | AU2005230897B2 (en) |
BR (1) | BRPI0509384A (en) |
CA (1) | CA2561632A1 (en) |
CY (1) | CY1107223T1 (en) |
DE (1) | DE602005004393T2 (en) |
DK (1) | DK1737820T3 (en) |
ES (1) | ES2297695T3 (en) |
HR (1) | HRP20080145T3 (en) |
PL (1) | PL1737820T3 (en) |
PT (1) | PT1737820E (en) |
SI (1) | SI1737820T1 (en) |
TW (1) | TWI344954B (en) |
WO (1) | WO2005097745A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US8853419B2 (en) | 2010-01-27 | 2014-10-07 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102659664B (en) * | 2012-03-28 | 2015-01-21 | 中国计量学院 | Method for synthesizing and separating Laalo Perrin and analogues thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062200A2 (en) * | 2002-01-24 | 2003-07-31 | Merck Frosst Canada & Co. | Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
WO2005013985A1 (en) * | 2003-08-07 | 2005-02-17 | Merck Sharp & Dohme Limited | Treatment for alzheimer's disease and related conditions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272787B1 (en) | 1986-11-14 | 1992-05-06 | Takasago International Corporation | Catalytic production of optically active carboxylic acid |
-
2005
- 2005-03-29 ES ES05732832T patent/ES2297695T3/en active Active
- 2005-03-29 EP EP05732832A patent/EP1737820B1/en active Active
- 2005-03-29 AU AU2005230897A patent/AU2005230897B2/en not_active Ceased
- 2005-03-29 DK DK05732832T patent/DK1737820T3/en active
- 2005-03-29 DE DE602005004393T patent/DE602005004393T2/en active Active
- 2005-03-29 PL PL05732832T patent/PL1737820T3/en unknown
- 2005-03-29 WO PCT/US2005/010501 patent/WO2005097745A1/en active IP Right Grant
- 2005-03-29 JP JP2007506467A patent/JP5239071B2/en not_active Expired - Fee Related
- 2005-03-29 AT AT05732832T patent/ATE384046T1/en active
- 2005-03-29 CN CN2005800108462A patent/CN1942440B/en not_active Expired - Fee Related
- 2005-03-29 PT PT05732832T patent/PT1737820E/en unknown
- 2005-03-29 TW TW094109815A patent/TWI344954B/en not_active IP Right Cessation
- 2005-03-29 CA CA002561632A patent/CA2561632A1/en not_active Abandoned
- 2005-03-29 BR BRPI0509384-8A patent/BRPI0509384A/en not_active IP Right Cessation
- 2005-03-29 SI SI200530149T patent/SI1737820T1/en unknown
- 2005-04-01 AR ARP050101298A patent/AR048459A1/en not_active Application Discontinuation
- 2005-04-01 US US11/097,565 patent/US7576118B2/en not_active Expired - Fee Related
-
2008
- 2008-02-29 CY CY20081100240T patent/CY1107223T1/en unknown
- 2008-03-28 HR HR20080145T patent/HRP20080145T3/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062200A2 (en) * | 2002-01-24 | 2003-07-31 | Merck Frosst Canada & Co. | Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
WO2005013985A1 (en) * | 2003-08-07 | 2005-02-17 | Merck Sharp & Dohme Limited | Treatment for alzheimer's disease and related conditions |
Non-Patent Citations (1)
Title |
---|
NOYORI ET AL.: "Asymetric synthesis of isoquinoline alkaloids by homogeneous catalysis", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 108, 1986, pages 7117 - 7119, XP002337343 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9126932B2 (en) | 2008-07-23 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9522133B2 (en) | 2008-07-23 | 2016-12-20 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US9108969B2 (en) | 2008-08-27 | 2015-08-18 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8853419B2 (en) | 2010-01-27 | 2014-10-07 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US11149292B2 (en) | 2010-01-27 | 2021-10-19 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US9175320B2 (en) | 2010-01-27 | 2015-11-03 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US9447041B2 (en) | 2010-01-27 | 2016-09-20 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US11674163B2 (en) | 2010-01-27 | 2023-06-13 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11896578B2 (en) | 2015-01-06 | 2024-02-13 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US10676435B2 (en) | 2015-06-22 | 2020-06-09 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
US11091435B2 (en) | 2015-06-22 | 2021-08-17 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1737820A1 (en) | 2007-01-03 |
DE602005004393T2 (en) | 2009-01-08 |
ES2297695T3 (en) | 2008-05-01 |
CN1942440B (en) | 2011-09-14 |
DK1737820T3 (en) | 2008-04-28 |
US7576118B2 (en) | 2009-08-18 |
AU2005230897B2 (en) | 2011-03-03 |
EP1737820B1 (en) | 2008-01-16 |
CY1107223T1 (en) | 2012-11-21 |
JP2007532488A (en) | 2007-11-15 |
SI1737820T1 (en) | 2008-04-30 |
TWI344954B (en) | 2011-07-11 |
CN1942440A (en) | 2007-04-04 |
HRP20080145T3 (en) | 2008-04-30 |
PT1737820E (en) | 2008-03-17 |
AU2005230897A1 (en) | 2005-10-20 |
ATE384046T1 (en) | 2008-02-15 |
US20050222428A1 (en) | 2005-10-06 |
AR048459A1 (en) | 2006-04-26 |
DE602005004393D1 (en) | 2008-03-06 |
CA2561632A1 (en) | 2005-10-20 |
TW200606145A (en) | 2006-02-16 |
JP5239071B2 (en) | 2013-07-17 |
BRPI0509384A (en) | 2007-09-18 |
PL1737820T3 (en) | 2008-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1737820B1 (en) | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives | |
JP3320488B2 (en) | Ferrocenyl diphosphine as a ligand in homogeneous catalysts | |
JP4153302B2 (en) | Hydrogen transfer process and catalyst | |
US7601667B2 (en) | Sulfonate catalyst and method of producing alcohol compound using the same | |
JPH09249677A (en) | Chiral ruthenium complex, its production and enantiomer selective transfer hydrogenation of prochiral ketone | |
US6897323B2 (en) | Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same | |
WO2008077560A1 (en) | Process for the preparation of optically active 2-amino-1-phenylethanols | |
JP2018039757A (en) | Method for producing imidazole derivative | |
KR101579991B1 (en) | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | |
JP5172124B2 (en) | Method for producing optically active quinuclidinols having a substituent at the 2-position | |
KR101579992B1 (en) | Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use | |
JP2000319288A (en) | Optically active 1-2-bis(dialkylphosphino)benzene derivative and its production, and rhodium metal complex with the same as ligand | |
JPWO2016043254A1 (en) | Process for producing optically active valeric acid derivatives | |
US20030055245A1 (en) | Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof | |
US6979742B1 (en) | Process for obtaining enantiomers of thienylazolylalcoxyethanamines | |
JP4422808B2 (en) | Trans- (R, R) -actinol | |
JP2019218402A (en) | Method for producing optically active valeric acid derivative | |
JP4011956B2 (en) | Novel synthesis method of (3aS) -5,5-dioxo-2,3,3a, 4-tetrahydro-1H-pyrrolo [2,1-c] [1,2,4] benzothiadiazine | |
JP5232374B2 (en) | Method for producing optically active quinuclidinols having a substituent at the 2-position | |
EP2041070A1 (en) | Method for producing optically active 3-aminocarboxylic acid esters | |
US20060142589A1 (en) | Process for obtaining enantiomers of Cizolirtine | |
KR20230087545A (en) | Asymmetric shift hydrogenation of 2-aryl substituted bicyclic pyridine ketones in the presence of a chiral ruthenium catalyst | |
JP2005306804A (en) | Method for producing optically active 3-quinuclidinol | |
EP0422944A1 (en) | Chiral sultams | |
JP4339074B2 (en) | Process for producing optically active 1,2-bis (3,5-dimethylphenyl) -1,2-ethanediamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 3526/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2561632 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007506467 Country of ref document: JP Ref document number: 2005732832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580010846.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005230897 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005230897 Country of ref document: AU Date of ref document: 20050329 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005230897 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005732832 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0509384 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005732832 Country of ref document: EP |